CR11169A - Oxazolidinonas sustituidas y su uso - Google Patents

Oxazolidinonas sustituidas y su uso

Info

Publication number
CR11169A
CR11169A CR11169A CR11169A CR11169A CR 11169 A CR11169 A CR 11169A CR 11169 A CR11169 A CR 11169A CR 11169 A CR11169 A CR 11169A CR 11169 A CR11169 A CR 11169A
Authority
CR
Costa Rica
Prior art keywords
oxazolidinones
replaced
formula
diseases
prophylaxis
Prior art date
Application number
CR11169A
Other languages
English (en)
Inventor
Swen Allerheiligen
Mark Jean Gnoth
Christoph Gerdes
Degenfeld Georges Von
Suzanne Rohrig
Elke Dittrich-Wengenroth
Anja Buchmuller
Elizabeth Perzborn
Murat Mertoglu
Michael Harter
Metin Akbaba
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39765012&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11169(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR11169A publication Critical patent/CR11169A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a nuevas oxazolidinonas sustituidas de formula (I), a procedimientos para su preparacion, a su uso para el tratamiento y/o profilaxis de enfermedades asi como a su uso para la preparacion de medicamentos para el tratamiento y/o profilaxis de enfermedades, de forma particular de enfermedades tromboembolicas. Formula (I) con R' = formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) o (Ii).
CR11169A 2007-06-20 2009-12-15 Oxazolidinonas sustituidas y su uso CR11169A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007028320A DE102007028320A1 (de) 2007-06-20 2007-06-20 Substituierte Oxazolidinone und ihre Verwendung

Publications (1)

Publication Number Publication Date
CR11169A true CR11169A (es) 2010-07-01

Family

ID=39765012

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11169A CR11169A (es) 2007-06-20 2009-12-15 Oxazolidinonas sustituidas y su uso

Country Status (26)

Country Link
US (1) US20100184767A1 (es)
EP (1) EP2167495A1 (es)
JP (1) JP2010530385A (es)
KR (1) KR20100029213A (es)
CN (1) CN101772496A (es)
AR (1) AR067058A1 (es)
AU (1) AU2008266527A1 (es)
BR (1) BRPI0813263A2 (es)
CA (1) CA2692172A1 (es)
CL (1) CL2008001703A1 (es)
CO (1) CO6251282A2 (es)
CR (1) CR11169A (es)
DE (1) DE102007028320A1 (es)
DO (1) DOP2009000287A (es)
EC (1) ECSP099806A (es)
GT (1) GT200900318A (es)
IL (1) IL202073A0 (es)
MA (1) MA31570B1 (es)
MX (1) MX2009013710A (es)
PA (1) PA8784101A1 (es)
PE (1) PE20090333A1 (es)
RU (1) RU2010101302A (es)
TN (1) TN2009000484A1 (es)
TW (1) TW200914447A (es)
UY (1) UY31136A1 (es)
WO (1) WO2008155034A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
JP2014506448A (ja) 2011-01-19 2014-03-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 凝固因子の阻害剤に対する結合タンパク質
CZ2012114A3 (cs) * 2012-02-17 2013-02-20 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
US20150299160A1 (en) * 2012-04-16 2015-10-22 Ranbaxy Laboratories Limited Process for the preparation of rivaroxaban and intermediates thereof
JP6186434B2 (ja) * 2012-07-18 2017-08-23 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 窒素複素環誘導体及びその医薬品への応用
CN102746250B (zh) * 2012-07-24 2016-03-02 瑞阳制药有限公司 N-[[3-(3-氟-4-吗啉基-4-基-苯基)-2-恶唑酮基-5-基]甲基]-2-甲氨基-苯甲酰胺的制备方法
CN103833724A (zh) * 2012-11-20 2014-06-04 上海医药工业研究院 一种5-氯噻吩-2-甲酰氯的制备方法
CN104163819A (zh) * 2013-05-17 2014-11-26 天津药物研究院 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
ES2761571T3 (es) 2013-06-20 2020-05-20 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido como acaricidas e insecticidas
JP2016526538A (ja) 2013-06-20 2016-09-05 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺ダニ剤及び殺虫剤としてのアリールスルフィド誘導体及びアリールスルホキシド誘導体
BR112016000241B1 (pt) 2013-07-08 2021-06-22 Bayer Cropscience Aktiengesellschaft Compostos pesticidas derivados de sulfeto de arila e sulfóxido de arila, formulação, seus usos, método para controle de pragas e método de proteção de semente ou planta
CN104016975B (zh) * 2014-06-27 2017-01-11 深圳翰宇药业股份有限公司 利伐沙班的制备方法
CN104447729A (zh) * 2014-12-05 2015-03-25 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
CN111699184B (zh) * 2018-02-26 2023-05-23 住友化学株式会社 噁唑烷酮化合物的制造方法
KR102422628B1 (ko) 2020-03-20 2022-07-18 마인도어 사회적협동조합 보드 게임 도구

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
ID22176A (id) 1996-10-14 1999-09-09 Bayer Ag Turunan pirazola tersubstitusi-heterosiklilmetil yang baru
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007032345A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102007032347A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs

Also Published As

Publication number Publication date
IL202073A0 (en) 2010-06-16
EP2167495A1 (de) 2010-03-31
PA8784101A1 (es) 2009-02-09
UY31136A1 (es) 2009-01-30
AU2008266527A1 (en) 2008-12-24
PE20090333A1 (es) 2009-04-15
RU2010101302A (ru) 2011-07-27
DOP2009000287A (es) 2010-01-31
GT200900318A (es) 2010-10-04
AR067058A1 (es) 2009-09-30
CN101772496A (zh) 2010-07-07
WO2008155034A1 (de) 2008-12-24
ECSP099806A (es) 2010-01-29
TW200914447A (en) 2009-04-01
US20100184767A1 (en) 2010-07-22
JP2010530385A (ja) 2010-09-09
KR20100029213A (ko) 2010-03-16
TN2009000484A1 (en) 2011-03-31
BRPI0813263A2 (pt) 2014-12-30
MX2009013710A (es) 2010-02-01
CA2692172A1 (en) 2008-12-24
MA31570B1 (fr) 2010-08-02
CO6251282A2 (es) 2011-02-21
DE102007028320A1 (de) 2008-12-24
CL2008001703A1 (es) 2008-12-26

Similar Documents

Publication Publication Date Title
CR11169A (es) Oxazolidinonas sustituidas y su uso
HN2009001597A (es) 4-aril-1, 4-dihidro-1,6-naftiridinamidas sustituidas y su uso
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
CR20140392A (es) Dihidropirazolonas sustituidas
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
CR10157A (es) Compuestos químicos
PA8740901A1 (es) Compuestos organicos
UY31228A1 (es) Ariloxazoles sustituidos y su uso
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
CR20120264A (es) Compuestos
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
MX2010009645A (es) Derivados novedosos de aminometil benceno.
ECSP10010192A (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antiinflamatorios
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
UY29149A1 (es) Tiazolil-dihidro-indazoles
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
PA8678901A1 (es) Derivados de quinolina como agentes antibacteriales
UY30788A1 (es) Compuestos quimicos
BR112013005224A2 (pt) "agonistas de adenosina a1 para o tratamento de glaucoma e hipertensão ocular".
CO6382113A2 (es) Compuestos quimicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)